EXHIBIT A

MAY 1997 VOLUME 46 SUPPLEMENT 1

diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION®
www.diabetes.org/diabetes

ABSTRACT BOOK

57th Annual Meeting and Scientific Sessions

Saturday, June 21 — Tuesday, June 24, 1997

Hynes Convention Center
Boston, Massachusetts

DIAEAZ 46 Supplement (1) 1A–434 (1997)
ISSN 0012-1797

0116

Pramlintide, an Analog of Human Amylin Improves Glycemic Control in Patients with Type II Diabetes Requiring Insulin.

ROBERT THOMPSON*[1], LEEANNE PEARSON*[1], STEVEN SCHOENFELD*[1], ORVILLE KOLTERMAN*[1]. *San Diego, CA*

The effects of 4 weeks of subcutaneous administration of pramlintide, (Pr) an analog of human amylin, on glycemic control in 203 patients with Type II diabetes mellitus requiring insulin were examined in a randomized, double-blind, placebo-controlled, parallel-group trial. Statistically significant reductions in serum fructosamine concentration were observed in the Pr 30 μg QID group (17.5±4.9 μmol/L), the Pr 60 μg TID group (24.1±4.9 μmol/L) and the Pr 60 μg QID group (22.6±4.1 μmol/L) compared to placebo (PBO) (3.5±3.8 μmol/L). There also were statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at Week 4 within the Pr 60 μg TID group (28%) and the Pr 60 μg QID group (31%) compared to PBO (10%). Consistent with the reduction in fructosamine, there were also statistically significant reductions in HbA_{1c} in the Pr 30 μg QID group (0.53±0.07%), the Pr 60 μg TID group (0.58±0.07%) and the Pr 60 μg QID group (0.51±0.08%) compared to placebo (0.27±0.08%). Based on RBC lifespan, and assuming stable glycemic control, these reductions in HbA1c in the Pr groups should increase over the following 2-3 months. The reductions in fructosamine and HbA_{1c} were accompanied by a statistically significant reduction in fasting total and LDL cholesterol. In contrast to treatment with insulin alone, there were trends towards decreased body weight in the Pr 60 μg TID and 60 μg QID groups. Furthermore, the incidence of hypoglycemia was no greater in any Pr group than in placebo. In conclusion, measurement of similar changes in both serum fructosamine concentration and HbA_{1c} suggests that pramlintide therapy for 28 days improves glycemic control in patients with Type II diabetes mellitus requiring insulin.

SEP - 7 2004

PTO/SB/17 (10-02)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($)

Complete if Known	
Application Number	09/445,517
Filing Date	12/06/1999
First Named Inventor	DUFT
Examiner Name	DEVI, SARVAMANGALA J N
Art Unit	1645
Attorney Docket No.	030639.0044.CPA1

METHOD OF PAYMENT *(check all that apply)*

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number: 50-1273

Deposit Account Name: BROBECK, PHLEGER & HARRISON

The Commissioner is authorized to: *(check all that apply)*

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, **except for the filing fee** to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1001	740	2001	370	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	510	2003	255	Plant filing fee	
1004	740	2004	370	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) ($)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims		Fee from below	Fee Paid
Total Claims		-20** =	X	=
Independent Claims		- 3** =	X	=
Multiple Dependent				=

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for *ex parte* reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	400	2252	200	Extension for reply within second month	
1253	920	2253	460	Extension for reply within third month	460.00
1254	1,440	2254	720	Extension for reply within fourth month	
1255	1,960	2255	980	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,280	2453	640	Petition to revive - unintentional	
1501	1,280	2501	640	Utility issue fee (or reissue)	
1502	460	2502	230	Design issue fee	
1503	620	2503	310	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	740	2809	370	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	740	2810	370	For each additional invention to be examined (37 CFR 1.129(b))	
1801	740	2801	370	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3) ($)

SUBMITTED BY				(Complete *if applicable*)	
Name (Print/Type)	BRADFORD J. DUFT	Registration No. (Attorney/Agent)	32,219	Telephone	858.720.2500
Signature				Date	12/5/2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**